ANTIFLU

Innovative anti-influenza drugs excluding viral escape

Coordinatore	MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.    more  Organization address address: Hofgartenstrasse 8 city: MUENCHEN postcode: 80539 contact info Titolo: Ms. Nome: Birgit Cognome: Gieding Email: send email Telefono: +49 30 28460 125 Fax: +49 30 28460 242
Nazionalità Coordinatore	Germany [DE]
Totale costo	7˙821˙684 €
EC contributo	5˙999˙998 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-INFLUENZA-2010
Funding Scheme	CP-FP
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-06-01   -   2016-05-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.  Organization address address: Hofgartenstrasse 8 city: MUENCHEN postcode: 80539 contact info Titolo: Ms. Nome: Birgit Cognome: Gieding Email: send email Telefono: +49 30 28460 125 Fax: +49 30 28460 242	DE (MUENCHEN)	coordinator	1˙459˙128.00
2	LEAD DISCOVERY CENTER GMBH  Organization address address: OTTO HAHN STRASSE 15 city: DORTMUND postcode: 44227 contact info Titolo: Dr. Nome: Michael Cognome: Hamacher Email: send email Telefono: +49 231 9742 7012 Fax: +49 231 9742 7039	DE (DORTMUND)	participant	1˙099˙860.00
3	VICHEM CHEMIE KUTATO KFT  Organization address address: HERMANN OTTO UTCA 15 city: BUDAPEST postcode: 1022 contact info Titolo: Prof. Nome: György Cognome: Kéri Email: send email Telefono: +36 1 4872080 Fax: +36 1 7999990	HU (BUDAPEST)	participant	596˙500.00
4	AARHUS UNIVERSITET  Organization address address: Nordre Ringgade 1 city: AARHUS C postcode: 8000 contact info Titolo: Ms. Nome: Karin Cognome: Sutherland Email: send email Telefono: +45 89 42 55 48	DK (AARHUS C)	participant	536˙576.00
5	ARTTIC  Organization address address: Rue du Dessous des Berges 58A city: PARIS postcode: 75013 contact info Titolo: Mr. Nome: Bruno Cognome: Cucinelli Email: send email Telefono: +33 1 53 94 54 61 Fax: +33 1 53 94 54 70	FR (PARIS)	participant	420˙000.00
6	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE  Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ contact info Titolo: Ms. Nome: Tatjana Cognome: Palalic Email: send email Telefono: +44 207 594 3866 Fax: +44 207 594 3868	UK (LONDON)	participant	403˙778.00
7	FORSCHUNGSVERBUND BERLIN E.V.  Organization address address: Rudower Chaussee 17 city: BERLIN postcode: 12489 contact info Titolo: Dr. Nome: Anne Cognome: Höner Email: send email Telefono: +49 30 94793286 Fax: +49 30 94793109	DE (BERLIN)	participant	400˙000.00
8	MEDITOX S.R.O  Organization address address: POD ZAMKEM 279 city: KONAROVICE postcode: 28125 contact info Titolo: Mr. Nome: Jan Cognome: Zabsky Email: send email Telefono: +420 313 129 374 Fax: +420 313 129 366	CZ (KONAROVICE)	participant	333˙556.00
9	RiboTask ApS  Organization address address: UNSBJERGVEJ 2 A city: Odense SO postcode: DK-5220 contact info Titolo: Dr. Nome: Jesper Cognome: Wengel Email: send email Telefono: +45 2084 6872 Fax: +45 6315 0023	DK (Odense SO)	participant	300˙000.00
10	THE HEBREW UNIVERSITY OF JERUSALEM.  Organization address address: GIVAT RAM CAMPUS city: JERUSALEM postcode: 91904 contact info Titolo: Ms. Nome: Hani Cognome: Ben-Yehuda Email: send email Telefono: +972 2 6586676 Fax: +972 2 6513205	IL (JERUSALEM)	participant	250˙560.00
11	INSTITUT PASTEUR  Organization address address: RUE DU DOCTEUR ROUX 25-28 city: PARIS CEDEX 15 postcode: 75724 contact info Titolo: Dr. Nome: Nadia Cognome: Khelef Email: send email Telefono: +33 1 4061 3378 Fax: +33 1 4061 3940	FR (PARIS CEDEX 15)	participant	200˙040.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'ANTIFLU is to develop innovative drugs against influenza virus infections based on a novel concept that precludes the development of viral resistance and ensures efficacy against upcoming pandemic influenza strains. Viral replication is known to depend on multiple host factors. Whilst traditional anti-influenza treatments usually target viral factors, ANTIFLU will aim at drugs interfering with host-response pathways. The concept of drugs targeting human factors, established in treatment of other diseases, has yet not been sufficiently explored for treatment of viral infections, although it bears compelling advantages over conventional antiviral therapies: (i) the avoidance of viral escape mutants and (ii) the broad coverage against unprecedented viral variants. ANTIFLU aims to fully exploit this potent approach to fill critical gaps in our current treatment and prevention options against seasonal and pandemic influenza virus infections. By building upon an existing panel of potent human targets and firm knowledge derived from FP6 project RIGHT, an interdisciplinary consortium will pursue the identification and validation of small molecule ligands and inhibitory RNA molecules effective against influenza infection. Promising modulators will form the basis to generate lead molecules that will be further refined to yield clinically applicable therapeutics. Initial preclinical studies will aim at providing proof of concept in animal models, safety and toxicology profiles. They will allow initiating complete clinical trials immediately after the phase of FP7 support, thanks to the commitment already taken by investors from the private sector. The consortium includes several SMEs, internationally renowned research groups and clinical institutions with extensive experience in anti-influenza treatment and clinical trials. An already agreed common exploitation model will provide a smooth route to market and optimal use of the project results.'

Introduzione (Teaser)

Seasonal influenza infections and the threat of pandemic viral strains scream for innovative measures. The European ANTIFLU study proposes to target the host instead of the virus itself.